# A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

> **NCT07535034** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Crystalys Therapeutics** · enrollment: 90 (estimated)

## Conditions studied

- Gout

## Interventions

- **DRUG:** Dotinurad
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07535034
- **Lead sponsor:** Crystalys Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-07
- **Final completion:** 2027-08
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07535034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07535034, "A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07535034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*